Pharmaceuticals: Why ad spending’s ailing
March 28, 2013
A number of ad categories have increased spending over the past few years following deep declines during the height of the recession.
Pharmaceuticals is not one of them.
Even as positive economic news builds, including a decrease in the unemployment rate, an increase in home building starts and a surge in the stock market, drug companies have reigned in their ad budgets.
Unlike many other categories, such as automotive and retail, pharmaceutical spending is tied not so much to the economy as to the state of the industry itself, and right now the mood is one of extreme caution.
Last year GlaxoKlineSmith reached a $3 billion settlement with the Justice Department over the marketing and development of its drugs. The government accused the British company of, among other things, advertising its drugs to treat ailments they were not approved for.
“Overall the business in the past several years has taken a more cautious approach to marketing in response to fears about regulation,” notes Jon Swallen, chief research officer at Kantar Media North America.
No one wants to be the next GlaxoKlineSmith, and in response many companies have pulled back on their advertising.
Last year spending in the category declined 3.8 percent, according to data crunched by Kantar and Nomura, from $7.6 billion to $7.31 billion.
It was the third-biggest decline for any top-20 ad category, behind only office supplies (down 10.3 percent) and media and entertainment (down 4.2 percent).
No individual pharmaceutical advertiser finished among the top 10 for 2012, according to Kantar. Pfizer was among the top seven until 2011.
Pharmaceutical advertising has dropped sharply in magazines as well as spot television, where spending plunged 30 percent last year, according to the TVB.
The other issue holding back spending is that there hasn’t been a major new drug introduction in some years. With no major new drugs to promote, pharmaceutical companies have little reason to increase spending.
In the past, rollouts of drugs such as Viagra, Lipitor and Zoloft have triggered a huge amount of ad spending to familiarize the public with the purpose and benefits of the new medications.
“Part of the reason is there have not been any big blockbuster marketing launches for newly approved drugs,” Swallen says.
“That was traditionally the catalyst during the last half of the past decade, 2005 to 2010. The category was propelled by marketing introductions.”
And with no major introductions on the horizon, the pharmaceutical ad chill could last for years to come.
‘Big Brother’ boosts CBS to first in 18-49s
The coming slowdown in auto sales and advertising
How viewers plan to view the Olympics: On TV
The next wave: America’s Hispanics and the New America
Rachel, I think it may be my time to leave media
Tell us, what do you expect from the Rio Games?
Weekend TV: Skydiving without a parachute
MLB sprints past other sports leagues in OOH beacons
Big stink over missing Hillary in newspapers
‘America’s Got Talent’ just edges ‘Big Brother’
Programming blog: What’s canceled and renewed
Readers: New fall shows are looking better
The seven commandments of community newspapers
- Morgan Carroll rises to managing director at DigitasLBi Chicago
- Hwa-Shih Lee rises to SVP of digital at Palisades MediaGroup
- Katrien De Bauw becomes managing director at TBWA\Media Arts Lab
- Tori Socha rises to VP of original series at Spike TV
- Melissa Bell rises to publisher at Vox Media
- Michael Holderle becomes VP of integrated marketing at Entravision
- Lin-Manuel Miranda hosting 'PBS Arts Fall Festival'
- Idina Menzel starring in Lifetime's 'Beaches' remake
This week’s broadcast ratings
This week’s cable ratings
This month’s digital traffic data: June 2016
This week’s top-rated movies, songs and books
This week’s daypart ratings
This month’s new media traffic data
Needed: Print media buyer in Chicago
Digital media buyer wanted in El Segundo
Media buyer wanted in Austin
Digital media planner wanted in Salt Lake City
Direct mail media planner job in Minneapolis